Publication

Insulin-Like Growth Factor I Serum Levels Influence Ischemic Stroke Outcome

De Smedt, A., Brouns, R., Uyttenboogaart, M., De Raedt, S., Moens, M., Wilczak, N., Luijckx, G-J. & De Keyser, J., Aug-2011, In : Stroke. 42, 8, p. 2180-2185 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

Background and Purpose-Insulin-like growth factor I (IGF-I) is neuroprotective in animal models of stroke. We investigated whether serum IGF-I levels in patients with acute ischemic stroke influence stroke severity and outcome.

Methods-Concentrations of IGF-I and IGF binding protein 3 were measured in serum samples obtained within 6 hours after stroke onset from 255 patients who took part in the placebo arm of the United States and Canadian Lubeluzole in Acute Ischemic Stroke Study. Stroke severity was assessed with the National Institutes of Health Stroke Scale. Multivariate analysis was performed to assess the overall shift in modified Rankin Scale score and changes in the National Institutes of Health Stroke Scale score at 3 months. Survival curves were plotted using the Kaplan-Meier method, and the Cox proportional hazard model was used for multivariate analysis to investigate factors influencing survival.

Results-After controlling for statistically relevant risk factors, subjects with high IGF-I levels or IGF-I/IGF binding protein 3 ratios had a better neurological and functional outcome at 3 months. Baseline stroke severity was not different between high and low IGF-I groups. In contrast to the low IGF-I group, neurological symptoms gradually improved from Day 3 in the high IGF-I group.

Conclusions-Our results suggest that high serum IGF-I levels just after ischemic stroke onset are associated with neurological recovery and a better functional outcome. (Stroke. 2011;42:2180-2185.)

Original languageEnglish
Pages (from-to)2180-2185
Number of pages6
JournalStroke
Volume42
Issue number8
Publication statusPublished - Aug-2011

    Keywords

  • insulin-like growth factor I, ischemic stroke, outcome, CLINICAL-TRIAL, SCALE

ID: 5371148